Skip to main content

Table 2 Results of treatment

From: Clinical significance of tumor-infiltrating lymphocytes investigated using routine H&E slides in small cell lung cancer

 

Total

sTIL+

sTIL−

p

Response to chemotherapy (case)

   

0.030

Treatment Sensitive (CR + PR)

123

65

58

 

Treatment Resistant (SD + PD)

36

12

24

 

Response to TRT (case)*

   

0.045

Treatment Sensitive (CR + PR)

63

38

26

 

Treatment Resistant (SD + PD)

18

6

12

 

mOS (moths)

16

18

12

0.030

1, 2, 3-year OS rate

59.8%, 28.6%, 19.8%

72.2%, 37.5%, 25.1%

48.0%, 19.9%, 5.1%

0.030

1, 2, 3-year PFS rate

31.5%, 13.1%, 6.2%

37.2%, 21.0%, 14.0%

25.9%, 4.2%, 4.2%

0.013

1, 2, 3-year BMFS rate**

75.0%, 47.2%, 47.2%

75.1%, 66.0%, 66.0%

75.5%, 11.4%, 11.4%

0.023

  1. *Patients administratived TRT and chemotherapy
  2. **Patients with non-BM and non-PCI